Sequential™ Secures $3.5M to Develop AI-Powered Skin Health Solutions

Unlocking the Future of Skin Health: Sequential's Groundbreaking Initiative

Sequential™, a frontrunner in genomic testing utilizing non-invasive human clinical samples, has recently announced the successful closure of its first equity funding round, raising an impressive $3.5 million. The funding was co-led by industry specialists Sparkfood and Corundum Systems Biology (CSB), with significant contributions from Dermazone Holdings, SOSV, and Scrum Ventures, among others. With this latest investment, Sequential has amassed a total of $7.5 million in both dilutive and non-dilutive funding to date, positioning the company for rapid growth and innovation in the skincare arena.

Revolutionizing Skin Health with Data-Driven Insights

At the heart of Sequential's operations lies its ambition to advance skin health by quantifying how different ingredients and products, spanning consumer, biotech, and pharmaceutical sectors, impact microbial and host biomarkers. This is made possible through the use of their proprietary testing platform, which bridges the divide between complex biological data and actionable consumer insights. By integrating detailed microbial and molecular analyses, the company paves the way for the creation of reliable, effective, and scientifically valid products.

With over 50,000 samples, more than 4,000 ingredients tested, along with insights derived from over 10,000 global participants, Sequential has established one of the most comprehensive clinical databases within the skin health industry. The newly acquired funds are earmarked for the development of an AI-powered discovery engine that leverages Sequential's rich clinical dataset. This initiative aims to foster the prediction, optimization, and discovery of next-generation active compounds and innovative bioactive ingredients.

The Vision for Personal Care

“Our mission is to bring pharmaceutical-grade evidence and computational precision to personal care,” asserted Oliver Worsley, PhD, CEO and Co-Founder of Sequential.